Amgen Inc.

Chawita Netirojjanakul

Bin Wu

Leslie Phillip Miranda

Yuan Cheng

Yang Li

John Gordon Allen

James Richard Falsey

Bradley J Herberich

Jerry Ryan Holder

Junming Yie

Justin K Murray

Shu-Chen Lu

Jun Zhang

Shanaka Stanislaus

Michael Ollmann

Oliver Homann

Oh Kyu Yoon

Jing M Xu

Kelvin C Sham

Murielle M Veniant-Ellison

Jing Xu

Kelvin Sham

Murielle M Venient-Ellison

Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.

Method of treating or ameliorating metabolic disorders using GLP-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (GIPR)

The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.

RNAi constructs for inhibiting ASGR1 expression and methods of use thereof

Growing community of inventors

Sherman Oaks, CA, United States of America

Chawita Netirojjanakul